MICS safer and more effective than torsional phaco

Article

The new Custom Control Software on the MICS Millennium platform (Bausch & Lomb) results in less endothelial cell loss than torsional phacoemulsification performed on the Infiniti System (Alcon), according to a Greek study.

The new Custom Control Software on the MICS Millennium platform (Bausch & Lomb) results in less endothelial cell loss than torsional phacoemulsification performed on the Infiniti System (Alcon), according to a Greek study.

Panagiotis Zafirakis and colleagues from the Diagnostic and Therapeutic Eye Center, Hellenic Ophthalmochirourgiki, Athens conducted a randomized, comparative study of 120 eyes, which were assigned to phacoemulsification by MICS (60 eyes) or torsional ultrasound (60 eyes) modes. Bimanual phacoemulsification was performed using a quick chop technique.

Mean operating time (5.11 versus 7.30 minutes), effective phaco time (3±5.31 versus 9.37±6.80 seconds) and mean percentage of ultrasound power (6.67±1.66 versus 18.88±2.77) were statistically significantly shorter (p<0.01) with the MICS platform compared with the torsional system. Mean volume of irrigation fluid used (134±11.3 ml versus 175±27.5 ml) and mean endothelial cell loss (3.6% versus 5.3%) were also significantly lower with the MICS system (p<0.001). There were three capsular ruptures in the torsional group and none in the MICS group. Furthermore, there were seven cases of postoperative corneal fold or oedema in the torsional group and only one in the MICS group. Postoperative best-corrected visual acuity (BCVA) was similar in both groups.Overall, it was concluded, the MICS platform is a safer and more effective system than torsional phacoemulsification.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.